Biocon biologics receives European Commission approval for Vevzuo, Evfraxy Denosumab biosimilars for bone diseases

Biocon Ltd's arm, Biocon Biologics Ltd, has received European Commission authorisation for its Vevzuo and Evfraxy biosimilars, used to treat various bone diseases. Vevzuo addresses bone complications in cancer patients and giant cell tumors, while Evfraxy treats osteoporosis and bone loss related to hormone ablation or glucocorticoid therapy.

from Industry-Economic Times https://ift.tt/8wJmysh
via IFTTT